Maintenance immunosuppressive therapy in adult renal transplantation: A single center analysis

Transplant Immunology

Volumn 20, Issue 1-2, 2008, Pages 14-20

  Säemann, Marcus D ^a   Sunder Plassmann, Gere ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Immunosuppression; Kidney; Transplantation

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EQUORAL; EVEROLIMUS; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOIMMUN; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; CREATININE; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 56049099276     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.08.012     Document Type: Article

References (72)

1. Sayegh M.H., and Carpenter C.B. Transplantation 50 years later-progress, challenges, and promises. N Engl J Med 351 26 (2004) 2761
2. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., and Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 3 (2004) 378
3. Meier-Kriesche H.U., Schold J.D., and Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?. Am J Transplant 4 8 (2004) 1289
4. Womer K.L., Vella J.P., and Sayegh M.H. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 20 2 (2000) 126
5. Najafian B., and Kasiske B.L. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 17 2 (2008) 149
6. Davidson J., Wilkinson A., Dantal J., Dotta F., Haller H., Hernandez D., et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation vol. 75 (10 Suppl) (2003) SS3
7. Andany M.A., and Kasiske B.L. Dyslipidemia and its management after renal transplantation. J Nephrol 14 Suppl 4 (2001) S81
8. Hirsch H.H., and Suthanthiran M. The natural history, risk factors and outcomes of polyomavirus BK-associated nephropathy after renal transplantation. Nat Clin Pract Nephrol 2 5 (2006) 240
9. Kasiske B.L. Cardiovascular disease after renal transplantation. Semin Nephrol 20 2 (2000) 176
10. Meyers C.M., and Kirk A.D. Workshop on late renal allograft dysfunction. Am J Transplant 5 7 (2005) 1600
11. Kingston R.W., and Goldsmith D.J. Chronic renal allograft dysfunction: the evidence for a change in immunosuppression. Minerva Urol Nefrol 58 1 (2006) 23
12. Danovitch G.M. Immunosuppressive medications for renal transplantation: a multiple choice question. Kidney Int 59 1 (2001) 388
13. Shapiro R., Young J.B., Milford E.L., Trotter J.F., Bustami R.T., and Leichtman A.B. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 5 4 Pt 2 (2005) 874
14. Samaniego M., Becker B.N., and Djamali A. Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat Clin Pract Nephrol 2 12 (2006) 688
15. Kirk A.D. Meteorology and tolerance. Am J Transplant 6 4 (2006) 645
16. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., Chapman J.R., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 24 (2003) 2326
17. Kasiske B.L., Vazquez M.A., Harmon W.E., Brown R.S., Danovitch G.M., Gaston R.S., et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11 Suppl 15 (2000) S1
18. Hardinger K.L., Koch M.J., and Brennan D.C. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 24 9 (2004) 1159
19. Ekberg H., and Meier-Kriesche H.U. No robust conclusions to be drawn from clinical trials in the absence of an adequate control group. Transpl Int 20 1 (2007) 25
20. Meier-Kriesche H.U., Li S., Gruessner R.W., Fung J.J., Bustami R.T., Barr M.L., et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 6 5 Pt 2 (2006) 1111
21. Meier-Kriesche H.U., and Hricik D.E. Are we ready to give up on calcineurin inhibitors?. Am J Transplant 6 3 (2006) 445
22. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 6719 (1999) 530
23. Dantal J., Hourmant M., Cantarovich D., Giral M., Blancho G., Dreno B., et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351 9103 (1998) 623
24. Cantarovich D., Vistoli F., and Soulillou J.P. Immunosuppression minimization in kidney transplantation. Front Biosci 13 (2008) 1413
25. Kaplan B., Schold J.D., and Meier-Kriesche H.U. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 14 11 (2003) 2980
26. Webster A.C., Woodroffe R.C., Taylor R.S., Chapman J.R., and Craig J.C. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331 7520 (2005) 810
27. Bowman L.J., and Brennan D.C. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother 9 4 (2008) 635
28. Joss N., Staatz C.E., Thomson A.H., and Jardine A.G. Predictors of new onset diabetes after renal transplantation. Clin Transplant 21 1 (2007) 136
29. Maes B.D., Kuypers D., Messiaen T., Evenepoel P., Mathieu C., Coosemans W., et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 72 10 (2001) 1655
30. van Hooff J.P., Christiaans M.H., and van Duijnhoven E.M. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 19 Suppl 6 (2004) vi8
31. Kasiske B.L., Snyder J.J., Gilbertson D., and Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3 2 (2003) 178
32. Kuypers D.R., Claes K., Bammens B., Evenepoel P., and Vanrenterghem Y. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant 23 6 (2008) 2033
33. Weng J., Li Y., Xu W., Shi L., Zhang Q., Zhu D., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371 9626 (2008) 1753
34. Vincenti F., Friman S., Scheuermann E., Rostaing L., Jenssen T., Campistol J.M., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7 6 (2007) 1506
35. Smak Gregoor P.J., de Sevaux R.G., Ligtenberg G., Hoitsma A.J., Hene R.J., Weimar W., et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 13 5 (2002) 1365
36. Gelens M.A., Christiaans M.H., van Heurn E.L., van den Berg-Loonen E.P., Peutz-Kootstra C.J., and van Hooff J.P. High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. Transplantation 82 9 (2006) 1221
37. Ekberg H., Grinyo J., Nashan B., Vanrenterghem Y., Vincenti F., Voulgari A., et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 7 3 (2007) 560
38. Ekberg H., Tedesco-Silva H., Demirbas A., Vitko S., Nashan B., Gurkan A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357 25 (2007) 2562
39. Pascual M., Curtis J., Delmonico F.L., Farrell M.L., Williams Jr. W.W., Kalil R., et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 75 9 (2003) 1501
40. Batiuk T.D., Pazderka F., Enns J., DeCastro L., and Halloran P.F. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest 96 3 (1995) 1254
41. Batiuk T.D., Pazderka F., and Halloran P.F. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation 59 10 (1995) 1400
42. Birsan T., Loinig C., Bodingbauer M., Wekerle T., Rockenschaub S., Berlakovich G., et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience. Transplantation 78 12 (2004) 1787
43. Hecking M., Kainz A., Schillinger M., Posch C., Birsan T., Rasoul-Rockenschaub S., et al. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine. Transpl Int 21 3 (2008) 223
44. Mulay A.V., Hussain N., Fergusson D., and Knoll G.A. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 5 7 (2005) 1748
45. Thaunat O., Beaumont C., Chatenoud L., Lechaton S., Mamzer-Bruneel M.F., Varet B., et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 80 9 (2005) 1212
46. Vogelbacher R., Wittmann S., Braun A., Daniel C., and Hugo C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 84 11 (2007) 1492
47. Letavernier E., Bruneval P., Mandet C., Van Huyen J.P., Peraldi M.N., Helal I., et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2 2 (2007) 326
48. Weiner S.M., Sellin L., Vonend O., Schenker P., Buchner N.J., Flecken M., et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome-a single-centre experience and review of the literature. Nephrol Dial Transplant 22 12 (2007) 3631
49. Witzig T.E., Geyer S.M., Ghobrial I., Inwards D.J., Fonseca R., Kurtin P., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23 23 (2005) 5347
50. Hutson T.E., and Figlin R.A. Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park) 21 10 (2007) 1175
51. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 13 (2005) 1317
52. Descoeudres B., Giannini O., Graf T., Steiger J., and Mayr M. No effect of sirolimus for kaposi sarcoma in a renal transplant recipient. Transplantation 81 10 (2006) 1472
53. Lebbe C., Euvrard S., Barrou B., Pouteil-Noble C., Garnier J.L., Glotz D., et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 6 9 (2006) 2164
54. Boratynska M., Zmonarski S.C., and Klinger M. Reccurence of Kaposi's sarcoma after increased exposure to sirolimus. Int Immunopharmacol 6 13-14 (2006) 2018
55. Babel N., Eibl N., Ulrich C., Bold G., Sefrin A., Hammer M.H., et al. Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis 10 1 (2008) 59
56. Prestwich R.J., Errington F., Hatfield P., Merrick A.E., Ilett E.J., Selby P.J., et al. The immune system-is it relevant to cancer development, progression and treatment?. Clin Oncol (R Coll Radiol) 20 2 (2008) 101
57. Dittrich E., Schmaldienst S., Soleiman A., Hörl W.H., and Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 17 4 (2004) 215
58. Säemann M.D., Böhmig G.A., Österreicher C.H., Staffler G., Diakos C., Krieger P.M., et al. Suppression of primary T-cell responses and induction of alloantigen-specific hyporesponsiveness in vitro by the Janus kinase inhibitor tyrphostin AG490. Transplantation 70 8 (2000) 1215
59. Weichhart T., Werzowa J., Hörl W.H., and Saemann M.D. Biological action of rapamycin in renal transplantation. Am J Kidney Dis 51 3 (2008) 531 author reply 531
60. Augustine J.J., and Hricik D.E. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 1 5 (2006) 1080
61. Matas A.J., Kandaswamy R., Gillingham K.J., McHugh L., Ibrahim H., Kasiske B., et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 5 10 (2005) 2473
62. Ahsan N., Hricik D., Matas A., Rose S., Tomlanovich S., Wilkinson A., et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 68 12 (1999) 1865
63. Vanrenterghem Y., Lebranchu Y., Hene R., Oppenheimer F., and Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 70 9 (2000) 1352
64. Pascual J., van Hooff J.P., Salmela K., Lang P., Rigotti P., Budde K., et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 82 1 (2006) 55
65. Augustine J.J., and Hricik D.E. Minimization of immunosuppression in kidney transplantation. Curr Opin Nephrol Hypertens 16 6 (2007) 535
66. Laftavi M.R., Stephan R., Stefanick B., Kohli R., Dagher F., Applegate M., et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 137 3 (2005) 364
67. van den Ham E.C., Kooman J.P., Christiaans M.H., Nieman F.H., and van Hooff J.P. Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Transpl Int 16 5 (2003) 300
68. Opelz G., Dohler B., and Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5 4 Pt 1 (2005) 720
69. Calne R. "Prope" tolerance: induction, lymphocyte depletion with minimal maintenance. Transplantation 80 1 (2005) 6
70. Roussey-Kesler G., Giral M., Moreau A., Subra J.F., Legendre C., Noel C., et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 6 4 (2006) 736
71. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 18 4 (2007) 1046
72. Tinckam K.J., and Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol 1 3 (2006) 404